- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD) with Open-Label Extension (OLE)
This study is looking at a new medicine called Losmapimod for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It checks how safe the medicine is over a long time and if it causes any side effects, building on previous trials.
For: Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension
This study is looking into a new medicine called Losmapimod for people with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1). It's a small, early-stage study to see if the medicine is safe, how well people can take it, and if it affects their condition.
For: Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)Netherlands